AU2001248324B2 - Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy - Google Patents

Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy Download PDF

Info

Publication number
AU2001248324B2
AU2001248324B2 AU2001248324A AU2001248324A AU2001248324B2 AU 2001248324 B2 AU2001248324 B2 AU 2001248324B2 AU 2001248324 A AU2001248324 A AU 2001248324A AU 2001248324 A AU2001248324 A AU 2001248324A AU 2001248324 B2 AU2001248324 B2 AU 2001248324B2
Authority
AU
Australia
Prior art keywords
sub
formula
lower alkyl
tyrosine kinase
receptor tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001248324A
Other languages
English (en)
Other versions
AU2001248324A1 (en
Inventor
Robert Charles Atkins
Steven James Chadban
Mark Emmanuel Cooper
Richard Ernest Gilbert
Prudence Ann Hill
Darren James Kelly
David John Nikolic-Paterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Southern Health
Original Assignee
NIKOLIC PATERSON DAVID JOHN
University of Melbourne
Southern Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIKOLIC PATERSON DAVID JOHN, University of Melbourne, Southern Health filed Critical NIKOLIC PATERSON DAVID JOHN
Publication of AU2001248324A1 publication Critical patent/AU2001248324A1/en
Application granted granted Critical
Publication of AU2001248324B2 publication Critical patent/AU2001248324B2/en
Priority to AU2005244525A priority Critical patent/AU2005244525A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001248324A 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy Ceased AU2001248324B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005244525A AU2005244525A1 (en) 2000-03-03 2005-12-14 Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00810181 2000-03-03
EP00810181.8 2000-03-03
PCT/EP2001/002340 WO2001064200A2 (en) 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005244525A Division AU2005244525A1 (en) 2000-03-03 2005-12-14 Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Publications (2)

Publication Number Publication Date
AU2001248324A1 AU2001248324A1 (en) 2001-11-22
AU2001248324B2 true AU2001248324B2 (en) 2005-09-15

Family

ID=8174580

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001248324A Ceased AU2001248324B2 (en) 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
AU4832401A Pending AU4832401A (en) 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU4832401A Pending AU4832401A (en) 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Country Status (10)

Country Link
US (1) US7087608B2 (enExample)
EP (1) EP1259242B1 (enExample)
JP (1) JP2003525240A (enExample)
AT (1) ATE369860T1 (enExample)
AU (2) AU2001248324B2 (enExample)
CA (1) CA2401812C (enExample)
DE (1) DE60129934T2 (enExample)
ES (1) ES2291306T3 (enExample)
PT (1) PT1259242E (enExample)
WO (1) WO2001064200A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000186A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
DK1401415T3 (da) 2001-06-29 2006-10-16 Ab Science Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
ES2274993T3 (es) 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
ES2274075T3 (es) 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
JP2005504054A (ja) * 2001-08-25 2005-02-10 アラキス リミテッド 腎疾患の治療におけるアントラキノンの使用
US7332330B2 (en) * 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
WO2003057165A2 (en) 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
EP1509219A1 (en) * 2002-05-13 2005-03-02 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
CA2494695C (en) 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
JP4776537B2 (ja) * 2003-05-27 2011-09-21 ロベルト・ペール・ヘーガークヴィスト 糖尿病処置のためのチロシンキナーゼ阻害剤の使用
ATE395052T1 (de) * 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
CN1905876B (zh) 2003-11-17 2010-06-09 诺瓦提斯公司 二肽基肽酶iv抑制剂的用途
US9073997B2 (en) 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2602735B2 (ja) * 1989-09-27 1997-04-23 株式会社大塚製薬工場 抗活性酸素剤
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5721277A (en) 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
CA2214393A1 (en) 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JPH10182644A (ja) * 1996-11-01 1998-07-07 Takeda Chem Ind Ltd 三環性化合物、その製造法及び剤
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
WO2000009098A2 (en) 1998-08-13 2000-02-24 Novartis Ag Method for treating ocular neovascular diseases

Also Published As

Publication number Publication date
US7087608B2 (en) 2006-08-08
DE60129934T2 (de) 2008-05-08
HK1052864A1 (en) 2003-10-03
AU4832401A (en) 2001-09-12
US20030186977A1 (en) 2003-10-02
WO2001064200A2 (en) 2001-09-07
CA2401812A1 (en) 2001-09-07
CA2401812C (en) 2009-06-09
EP1259242B1 (en) 2007-08-15
JP2003525240A (ja) 2003-08-26
ATE369860T1 (de) 2007-09-15
EP1259242A2 (en) 2002-11-27
ES2291306T3 (es) 2008-03-01
PT1259242E (pt) 2007-11-15
DE60129934D1 (de) 2007-09-27
WO2001064200A3 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU2001248324B2 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
AU2001248324A1 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP6937812B2 (ja) 貧血治療のための組成物及び方法
KR102893133B1 (ko) 진행성 섬유화 간질성 폐 질환(pf-ild)의 치료를 위한 활성 제제들의 신규한 배합
KR20070099527A (ko) 유기 화합물의 조합물
AU2002307140B2 (en) Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders
AU2002307140A1 (en) Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders
MX2011000511A (es) Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis.
EP3890737B1 (en) Usp19 inhibitors for use in a method of treating obesity, insulin resistance and type ii diabetes
KR20220127824A (ko) 알파1-항트립신 결핍의 치료를 위한 4-((2-옥소피리딘-1(2h)-일)메틸)벤즈아미드
AU2005244525A1 (en) Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
HK1052864B (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
US20120277246A1 (en) Use of N-Phenyl-2-pyrimidineamine Derivatives Against Mast Cell-based Diseases Like Allergic Disorders
MX2007013741A (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica.
TWI293880B (en) Use of pdgf receptor tryosine kinase inhibitors for the treatment of diabetic nephropathy
MX2007013738A (es) Derivados de pirimidilaminobenzamida para sindrome hipereosinofilico.
JP2005508846A (ja) アレルギー性疾患のような肥満細胞系疾患に対するｎ−フェニル−２−ピリミジンアミン誘導体の使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired